摘要
目的比较ACH-TH(脂质体多柔比星+环磷酰胺+曲妥珠单克隆抗体序贯紫杉醇+曲妥珠单克隆抗体)与TCH(多西他赛+卡铂+曲妥珠单克隆抗体)2种新辅助化疗方案在HER-2阳性乳腺癌患者中的疗效差别。方法回顾性收集2017年1月1日至2020年1月31日就诊于东南大学附属中大医院、南京市第--医院、江苏省中医院和江苏省肿瘤医院等4家医院的HER-2阳性并接受新辅助化疗的36例乳腺癌患者临床资料,其中ACH-TH组17例,TCH组19例,采用Fisher确切概率法比较2组患者的pCR率及不良反应发生率。结果ACH-TH组的pCR率高于TCH组(13/17比4/19,P=0.002)。ACH-TH组骨髓抑制和脱发的发生率明显低于TCH组(2/17比10/19,P=0.014;0比19/19,P<0.001),而2组的心脏毒性、胃肠道反应、口腔黏膜反应、手足综合征等不良反应发生率比较,差异无统计学意义(P=1.000、1.000.0.216、0.487)。结论ACH-TH方案是HER-2阳性乳腺癌患者新辅助化疗的优选方案。
Objective To compare the fficacy of the ACH-TH regimen(liposomal-encapsulated doxorubicin+cyclophosphamide+trastuzumab,ollowed by paclitaxel+trastuzumab)and the TCH regimen(docetaxel+carboplatin+trastuzumab)for neoadjuvant chemotherapy of HER-2 positive breast cancer.Methods We retrospectively collected the clinical data of 36 HER-2 positive breast cancer patients who received neoadjuvant chemotherapy in four hospitals(Zhongda Hospital of Southeast Universily,Nanjing First Hospital,Jiangsu Provincial Hospital of Traditional Chinese Medicine and Jiangsu Provincial Cancer Hospital)from January 1,2017 to January 31,2020,including 17 cases in the ACH-TH group and 19 cases in the TCH group.The pathological complete response(pCR)rate and incidence of adverse reactions between the two groups were compared using Fisher's exact test.Results The pCR rate was 13/17 in the ACH-TH group,which was significantly higher than that in the TCH group(4/19)(P=0.002).The incidences of bone marrow suppression and alopecia in the ACH-TH group were significantly lower than those in the TCH group(2/17 us 10/19,P=0.014;0 us 19/19,P<0.001).However,there was no significant difference in the incidence of other adverse events such as cardiotoxicity,gastrointestinal reactions,oral mucosal reactions and hand-foot syndrome between the two groups(P=1.000,1.000,0.216,0.487).Conclusion ACH-TH regimen is the optimal regimen for neoadjuvant chemotherapy of HER-2 positive breast cancer patients.
作者
吕建鑫
朱月赟
张亚男
胡浩霖
王宝偲
曹欣华
韩丽飞
马號
Lyu Jianxin;Zhu Yueyun;Zhang Ya’nan;Hu Haolin;Wang Baocai;Cao Xinhua;Han Lifei;Ma Xiao(Department of Breast Surgery,Zhongda Hospital of Southeast Uniwersity,Nanjing 210009,China;Department of General Surgery,General Hospital of Eastern Theater Command,Nanjing 210008,China)
出处
《中华乳腺病杂志（电子版）》
CAS
CSCD
2023年第2期88-92,共5页
Chinese Journal of Breast Disease(Electronic Edition)
基金
国家自然科学基金青年基金资助项目(81502287)。
